# Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

> **NCT04391179** · PHASE2 · COMPLETED · sponsor: **University of Michigan** · enrollment: 99 (actual)

## Conditions studied

- COVID
- Corona Virus Infection
- Covid-19
- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Dipyridamole 100 Milligram(mg)
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04391179
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-31
- **Primary completion:** 2021-02-22
- **Final completion:** 2021-02-22
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391179, "Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04391179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*